filmov
tv
Apoptosis and venetoclax

Показать описание
Animation by Etsuko Uno, Walter and Eliza Hall Institute
This animation is in two parts.
Part 1: Apoptosis is a type of cell death that removes diseased and unwanted cells from the body. This part of the animation illustrates how apoptotic molecules are released from the mitochondria, an organelle inside the cell. It focuses on proteins that interact on the surface of the mitochondria to release apoptotic molecules. This release of proteins from the mitochondria is considered a point of no return and is therefore a critical step in the cell death process.
This animation is in two parts.
Part 1: Apoptosis is a type of cell death that removes diseased and unwanted cells from the body. This part of the animation illustrates how apoptotic molecules are released from the mitochondria, an organelle inside the cell. It focuses on proteins that interact on the surface of the mitochondria to release apoptotic molecules. This release of proteins from the mitochondria is considered a point of no return and is therefore a critical step in the cell death process.
Apoptosis and venetoclax
BCL2 inhibition and CLL: the role of venetoclax
Venetoclax Resistance: Mechanisms and Treatment Options
Mechanism of action of venetoclax (ABT-199) and its side effects
Current research into pro-apoptosis medication for leukemia
Harnessing apoptosis in AML
CLL Whiteboard #3: Mechanisms of Action of Anti-Apoptotic BCL2 Inhibitors
What is Venetoclax? | Dana-Farber Cancer Institute
Molecules in VR: Venetoclax, The First Approved BCL-2 Antagonist for Chronic Lymphocytic Leukemia
TLS in patients with CLL treated with venetoclax
Perspectives in AML treatment: targeting apoptosis without chemotherapy by using BH3-mimetics
The power of venetoclax
Venetoclax in Higher-Risk MDS/AML
Novel inducers of apoptosis in double-refractory CLL cells
Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)
Venetoclax in AML
Update on Venetoclax for CLL
Treating CLL after venetoclax or BTK inhibitors
Treating patients with poor-risk cytogenetics with venetoclax and HMAs
What is Venetoclax? #AML
Venetoclax in Chronic Lymphocytic Leukemia
Promising results for venetoclax across multiple hematological malignancies
What is the latest on Venetoclax?
BCL2 family changes associated with venetoclax resistance in multiple myeloma
Комментарии